1887

Abstract

How the overlap between the hepatitis B virus (HBV) reverse transcriptase (RT) and HBV S antigen (HBsAg) genes modulates the extent of HBV genetic variability is still an open question, and was investigated here. The rate of nucleotide conservation (≤1 % variability) followed an atypical pattern in the RT gene, due to an overlap between RT and HBsAg (69.9 % nucleotide conservation in the overlapping region vs 41.2 % in the non-overlapping region; <0.001), with a consequently lower rate of synonymous substitution within the overlapping region [median(interquartile range)dS = 3.1(1.5–7.4) vs 20.1(10.6–30.0);  = 3.249×10]. The most conserved RT regions were located within the YMDD motif and the N-terminal parts of the palm and finger domains, critical for RT functionality. These regions also corresponded to highly conserved HBsAg domains that are critical for HBsAg secretion. Conversely, the genomic region encoding the HBsAg antigenic loop (where immune-escape mutations are localized) showed a sharp decrease in the extent of conservation (40.6 %), which was less pronounced in the setting of human immunodeficiency virus (HIV)-driven immune suppression (48.8 % in HIV–HBV co-infection vs 21.5 % in mono-infected patients;  = 0.020). In conclusion, the overlapping reading frame and the immune system appear to have shaped the patterns of RT and HBsAg genetic variability. Highly conserved regions in RT and HBsAg may deserve further attention as novel therapeutic targets.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.046524-0
2013-01-01
2020-01-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/1/143.html?itemId=/content/journal/jgv/10.1099/vir.0.046524-0&mimeType=html&fmt=ahah

References

  1. Balzarini J. . ( 2007; ). Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. . Nat Rev Microbiol 5:, 583–597. [CrossRef] [PubMed]
    [Google Scholar]
  2. Blanchet M. , Sureau C. . ( 2006; ). Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. . J Virol 80:, 11935–11945. [CrossRef] [PubMed]
    [Google Scholar]
  3. Chang M. H. . ( 2010; ). Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. . Antivir Ther 15: (3 Pt B), 463–469. [CrossRef] [PubMed]
    [Google Scholar]
  4. Chisari F. V. , Isogawa M. , Wieland S. F. . ( 2010; ). Pathogenesis of hepatitis B virus infection. . Pathol Biol (Paris) 58:, 258–266. [CrossRef] [PubMed]
    [Google Scholar]
  5. Das K. , Xiong X. , Yang H. , Westland C. E. , Gibbs C. S. , Sarafianos S. G. , Arnold E. . ( 2001; ). Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). . J Virol 75:, 4771–4779. [CrossRef] [PubMed]
    [Google Scholar]
  6. Desmond C. P. , Bartholomeusz A. , Gaudieri S. , Revill P. A. , Lewin S. R. . ( 2008; ). A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. . Antivir Ther 13:, 161–175.[PubMed]
    [Google Scholar]
  7. François K. O. , Balzarini J. . ( 2012; ). Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. . Med Res Rev 32:, 349–387. [CrossRef] [PubMed]
    [Google Scholar]
  8. Gish R. G. , Satishchandran C. , Young M. , Pachuk C. . ( 2011; ). RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. . Antivir Ther 16:, 547–554. [CrossRef] [PubMed]
    [Google Scholar]
  9. Kohlstaedt L. A. , Wang J. , Friedman J. M. , Rice P. A. , Steitz T. A. . ( 1992; ). Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. . Science 256:, 1783–1790. [CrossRef] [PubMed]
    [Google Scholar]
  10. Lai M. W. , Lin T. Y. , Tsao K. C. , Huang C. G. , Hsiao M. J. , Liang K. H. , Yeh C. T. . ( 2012; ). Increased seroprevalence of HBV DNA with mutations in the S gene among individuals greater than 18 years old after complete vaccination. . Gastroenterology 143:, 400–407. [CrossRef] [PubMed]
    [Google Scholar]
  11. Locarnini S. A. , Yuen L. . ( 2010; ). Molecular genesis of drug-resistant and vaccine-escape HBV mutants. . Antivir Ther 15: (3 Pt B), 451–461. [CrossRef] [PubMed]
    [Google Scholar]
  12. Lok A. S. , McMahon B. J. . ( 2009; ). Chronic hepatitis B: update 2009. . Hepatology 50:, 661–662. [CrossRef] [PubMed]
    [Google Scholar]
  13. Maman Y. , Blancher A. , Benichou J. , Yablonka A. , Efroni S. , Louzoun Y. . ( 2011; ). Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins. . J Virol 85:, 4558–4566. [CrossRef] [PubMed]
    [Google Scholar]
  14. McMahon B. J. . ( 2004; ). Viral hepatitis in the Arctic. . Int J Circumpolar Health 63: (Suppl. 2), 41–48.[PubMed] [CrossRef]
    [Google Scholar]
  15. McMahon B. J. . ( 2009; ). The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. . Hepatol Int 3:, 334–342. [CrossRef] [PubMed]
    [Google Scholar]
  16. Mizokami M. , Orito E. . ( 1999; ). Molecular evolution of hepatitis viruses. . Intervirology 42:, 159–165. [CrossRef] [PubMed]
    [Google Scholar]
  17. Mizokami M. , Orito E. , Ohba K. , Ikeo K. , Lau J. Y. , Gojobori T. . ( 1997; ). Constrained evolution with respect to gene overlap of hepatitis B virus. . J Mol Evol 44: (Suppl. 1), S83–S90. [CrossRef] [PubMed]
    [Google Scholar]
  18. Pond S. L. , Frost S. D. , Muse S. V. . ( 2005; ). HyPhy: hypothesis testing using phylogenies. . Bioinformatics 21:, 676–679. [CrossRef] [PubMed]
    [Google Scholar]
  19. Torresi J. , Earnest-Silveira L. , Deliyannis G. , Edgtton K. , Zhuang H. , Locarnini S. A. , Fyfe J. , Sozzi T. , Jackson D. C. . ( 2002; ). Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. . Virology 293:, 305–313. [CrossRef] [PubMed]
    [Google Scholar]
  20. van der Sande M. A. , Waight P. , Mendy M. , Rayco-Solon P. , Hutt P. , Fulford T. , Doherty C. , McConkey S. J. , Jeffries D. . & other authors ( 2006; ). Long-term protection against carriage of hepatitis B virus after infant vaccination. . J Infect Dis 193:, 1528–1535. [CrossRef] [PubMed]
    [Google Scholar]
  21. WHO ( 2012; ). HBV Fact Sheet no. 204, July 2012. http://www.who.int/mediacentre/factsheets/fs204/en/
  22. Yang Z. . ( 2007; ). paml4: phylogenetic analysis by maximum likelihood. . Mol Biol Evol 24:, 1586–1591. [CrossRef] [PubMed]
    [Google Scholar]
  23. Yang Z. , Lauder I. J. , Lin H. J. . ( 1995; ). Molecular evolution of the hepatitis B virus genome. . J Mol Evol 41:, 587–596. [CrossRef] [PubMed]
    [Google Scholar]
  24. Zaaijer H. L. , van Hemert F. J. , Koppelman M. H. , Lukashov V. V. . ( 2007; ). Independent evolution of overlapping polymerase and surface protein genes of hepatitis B virus. . J Gen Virol 88:, 2137–2143. [CrossRef] [PubMed]
    [Google Scholar]
  25. Zhang Y. L. , Cheng T. , Cai Y. J. , Yuan Q. , Liu C. , Zhang T. , Xia D. Z. , Li R. Y. , Yang L. W. . & other authors ( 2010; ). RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo. . BMC Microbiol 10:, 214. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.046524-0
Loading
/content/journal/jgv/10.1099/vir.0.046524-0
Loading

Data & Media loading...

Supplements

Supplementary material 

PDF

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error